Guggenheim initiated coverage on Personalis with a new price target
$PSNL
Medical Specialities
Health Care
Guggenheim initiated coverage of Personalis with a rating of Buy and set a new price target of $6.00
Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.
| Date | Price Target | Rating | Analyst |
|---|---|---|---|
| 12/2/2025 | $11.00 | Equal-Weight | Morgan Stanley |
| 5/15/2025 | $6.00 | Buy | Guggenheim |
| 3/17/2025 | $8.00 | Buy | Canaccord Genuity |
| 2/6/2023 | $8.00 | Hold → Buy | Needham |
| 2/6/2023 | Hold → Buy | Needham | |
| 2/25/2022 | $30.00 → $24.00 | Outperform | Oppenheimer |
| 2/25/2022 | $30.00 → $18.00 | Buy | Citigroup |
| 2/25/2022 | $50.00 → $38.00 | Buy | HC Wainwright & Co. |
4 - Personalis, Inc. (0001527753) (Issuer)
4 - Personalis, Inc. (0001527753) (Issuer)
4 - Personalis, Inc. (0001527753) (Issuer)
Clinical test volume surged 41% in Q4 over Q3 to 6,183 tests; full year volume of 16,233 tests outperforms initial 2025 projections Strong cash position of approximately $240 million provides capital for commercial expansion Secured pivotal Medicare coverage for breast cancer surveillance, validating ultrasensitive MRD technology Preliminary Q4 revenue of $17 to $18 million; preliminary full year revenue of $69 to $70 million Personalis, Inc. (NASDAQ:PSNL), a leader in advanced genomics for precision oncology, today reported certain unaudited preliminary financial and operational results for the fourth quarter and full year ended December 31, 2025. Fourth Quarter Strategic an
Issued on behalf of Oncolytics Biotech Inc. USANewsGroup.com News Commentary VANCOUVER, BC, Dec. 31, 2025 /PRNewswire/ -- The precision oncology market surged to $139.4 billion in 2025 and is racing toward $317.5 billion by 2035[1], driven by a fundamental shift in cancer treatment philosophy. Biomarker-guided therapy selection now enables oncology pharmacists and clinicians to match treatments to tumor-specific characteristics rather than relying on blind, one-size-fits-all protocols[2]. This convergence of diagnostic precision and therapeutic targeting defines the investment thesis for Oncolytics Biotech Inc. (NASDAQ:ONCY), Exact Sciences Corp. (NASDAQ:EXAS), Veracyte, Inc. (NASDAQ:VCYT),
Personalis, Inc. (NASDAQ:PSNL), a leader in advanced genomics for precision oncology, today announced the publication of a new study in Clinical Cancer Research, a journal of the American Association for Cancer Research (AACR). The paper, titled "Broad Utility of Ultrasensitive Analysis of ctDNA Dynamics across Solid Tumors Treated with Immunotherapy," details results from Dr. Rodrigo Toledo and a leading team at the Vall d'Hebron Institute of Oncology (VHIO) in Barcelona, Spain. The study provides compelling clinical evidence that the company's ultra-sensitive, tumor-informed molecular residual disease (MRD) assay, NeXT Personal®, can effectively predict patient outcomes across a diverse s
Bhandari to drive regulatory strategies for minimal residual disease (MRD) cancer test Personalis achieves ISO 13485:2016 certification, attesting to its ability to deliver medical devices and related services of the highest quality Personalis, Inc. (NASDAQ:PSNL), a leader in advanced genomic testing for precision oncology, today announced the appointment of Deepshikha Bhandari as SVP, Regulatory, Quality and Clinical Compliance. With over two decades of industry marketing and regulatory affairs experience, Ms. Bhandari will help the company navigate the regulatory requirements for the NeXT Personal® MRD test. She was most recently VP, Regulatory Affairs at GRAIL, and previously held se
Personalis, Inc. (NASDAQ:PSNL) today announced that it has appointed Kenneth J. Widder, M.D., to its Board of Directors. Dr. Widder currently serves on the boards of QuidelOrtho Corporation and Evoke Pharma, Inc. and has over 40 years of experience working with biomedical companies, having previously served as a founder, director and/or CEO of Sydnexis, Inc., OrphoMed, Inc., Sytera, Inc., NovaCardia, Inc., Santarus, Inc., and Molecular Biosystems Inc., and as a general partner at LVP Life Science Ventures (formerly Latterell Venture Partners) and Windamere Venture Partners. He holds an M.D. from Northwestern University and trained in pathology at Duke University. "We are delighted to ha
Personalis, Inc. (NASDAQ:PSNL), a leader in advanced genomics for precision oncology, today announced that John West, co-founder, CEO and member of the board of directors of Personalis, notified the Company of his decision to retire as CEO and a director at the end of the calendar year. Mr. West has served in the DNA sequencing field for over forty years, and co-founded Personalis with four Stanford professors in 2011. Effective December 31, 2022, Aaron Tachibana, Personalis Chief Financial Officer, will serve as interim CEO and Christopher Hall, Personalis SVP and Head, Diagnostics Business, will be promoted to President. Mr. West will continue to serve as an advisor to the Board. "We th
4 - Personalis, Inc. (0001527753) (Issuer)
8-K - Personalis, Inc. (0001527753) (Filer)
8-K - Personalis, Inc. (0001527753) (Filer)
424B5 - Personalis, Inc. (0001527753) (Filer)
Company Advances "Win-in-MRD" Strategy with Compelling Clinical Trial Data and Increasing Physician Adoption of NeXT Personal® Platform Personalis, Inc. (NASDAQ:PSNL), a leader in advanced genomics for precision oncology, today reported financial results for the third quarter ended September 30, 2025. The quarter was distinguished by significant operational momentum in its "Win-in-MRD" strategy, headlined by increasing clinical tests delivered and robust clinical evidence generation. Third Quarter 2025 and Recent Business Highlights Accelerated Clinical Adoption: Delivered 4,388 clinical tests, demonstrating robust 26% sequential increase over Q2 2025 and a 364% year-over-year growth fu
Personalis, Inc. (NASDAQ:PSNL), a leader in advanced genomics for precision oncology, announced today that it will release its third quarter 2025 financial results on Tuesday, November 4, 2025. In conjunction with the release, Personalis will host a conference call and webcast that day at 2:00 p.m. Pacific Time / 5:00 p.m. Eastern Time to discuss its financial results and recent highlights. Interested parties may access the call by dialing 877-451-6152 for domestic callers or 201-389-0879 for international callers. The live webinar of the call may be accessed by visiting the Events section of the company's website at investors.personalis.com. A replay of the webinar will be available shor
Strong Q2 Clinical Momentum with 59% Sequential Growth in Test Volume Personalis, Inc. (NASDAQ:PSNL), a leader in advanced genomics for precision oncology, today reported financial results for the second quarter ended June 30, 2025, and recent accomplishments of its "Win-in-MRD" strategy: Second Quarter 2025 and Recent Business Highlights Clinical Adoption Acceleration: Delivered 3,478 clinical tests in the second quarter, a 59% sequential increase over Q1 2025, demonstrating accelerating physician adoption of the NeXT Personal® platform Commercial Partnership Expansion: Broadened the strategic collaboration with Tempus AI, Inc. (Tempus) to add colorectal cancer, a major new indic
Morgan Stanley resumed coverage of Personalis with a rating of Equal-Weight and set a new price target of $11.00
Guggenheim initiated coverage of Personalis with a rating of Buy and set a new price target of $6.00
Canaccord Genuity initiated coverage of Personalis with a rating of Buy and set a new price target of $8.00
SC 13G/A - Personalis, Inc. (0001527753) (Subject)
SC 13G - Personalis, Inc. (0001527753) (Subject)
SC 13D/A - Personalis, Inc. (0001527753) (Subject)